As explored in my previous article (Medical Chronicle, October issue), a purely glucose-centric approach does not optimally resolve the issue of accelerated atherosclerotic cardiovascular disease (ASCVD) and it’s manifestations in type 2 diabetes (T2D). While there is a reduction in microvascular disease, we know from the big cardiovascular studies that patients aren’t getting much benefit in terms of macrovascular outcomes.  

Although the goal of these trials was to demonstrate non-inferiority to placebo, to the pleasant surprise of the trialists, some of these molecules resulted in a reduction in cardiovascular events

Please sign in to read more